Table 1 Patient demographics and baseline characteristics
Parameter | N = 240 |
|---|---|
Age, years | |
Mean (± SD) | 37.4 (± 9.27) |
Median (Q1; Q3) | 37.0 (31.0; 43.0) |
Min; Max | 18; 67 |
Sex, n (%) | |
Male | 71 (29.6) |
Female | 169 (70.4) |
Time since first MS symptom prior to study entry, years | |
Mean (± SD) | 10.35 (± 6.70) |
Median (Q1; Q3) | 9.42 (5.22; 14.26) |
Min; Max | 0.4; 38.5 |
Frequency of relapses during the year prior to fingolimod treatment, n (%) [95% CI] | |
Patients with no relapse | 47 (19.6) [14.8; 25.2] |
Patients with 1 relapse | 54 (22.5) [17.4; 28.3] |
Patients with 2 relapses | 102 (42.5) [36.2; 49.0] |
Patients with > 2 relapses | 37 (15.4) [11.1; 20.6] |
Number of MS relapses within the year prior to fingolimod treatment | |
Mean (± SD) | 1.6 (± 1.02) |
Median (Q1; Q3) | 2.0 (1.0; 2.0) |
Min; Max | 0; 4 |
Frequency of relapses in the 2 years prior to fingolimod treatment, n (%) [95% CI] | |
Patients with no relapse | 35 (14.6%) [10.4; 19.7] |
Patients with 1 relapse | 27 (11.3) [7.6; 15.9] |
Patients with 2 relapses | 70 (29.2) [23.5; 35.4] |
Patients with > 2 relapses | 108 (45.0) [38.6; 51.5] |
Number of MS relapses in the 2 years prior to fingolimod treatment | |
Mean (± SD) | 2.3 (± 1.46) |
Median (Q1; Q3) | 2.0 (1.0; 3.0) |
Min; Max | 0; 9 |
EDSS score for the 3 months prior to study entry or at the start of fingolimod treatment | |
Mean (± SD) | 3.4 (± 1.26) |
Median (Q1; Q3) | 3.5 (2.5; 4.5) |
Min; Max | 0; 6 |
Number of missed days of work during the 3 months prior to study entry | |
Mean (± SD) | 7.9 (± 19.66) |
Median (Q1; Q3) | 0.0 (0.0; 6.0) |
Min; Max | 0.0; 90.0 |